Esophagus to Small Intestine

Gastroenterology. 2023;165(1):61–70.e5

Sun D, Liu C, Zhu Y, Yu C, Guo Y, Sun D, Pang Y, Pei P, Du H, Yang L, Chen Y, Meng X, Liu Y, Zhang J, Schmidt D, Avery D, Chen J, Chen Z, Lv J, Kan H, Li L; China Kadoorie Biobank Collaborative Group

Long-term exposure to fine particulate matter and incidence of esophageal cancer: A prospective study of 0.5 million Chinese adults


Background and aims: Evidence is sparse and inconclusive on the association between long-term fine (≤ 2.5 μm) particulate matter (PM2.5) exposure and esophageal cancer. The authors aimed to assess the association of PM2.5 with esophageal cancer risk and compared the esophageal cancer risk attributable to PM2.5 exposure and other established risk factors.
Methods: This study included 510,125 participants without esophageal cancer at baseline from China Kadoorie Biobank. A high-resolution (1 x 1 km) satellite-based model was used to estimate PM2.5 exposure during the study period. Hazard ratios (HRs) and 95% confidence intervals [CIs] of PM2.5 with esophageal cancer incidence were estimated using Cox proportional hazard model. Population attributable fractions for PM2.5 and other established risk factors were estimated.
Results: There was a linear concentration-response relationship between long-term PM2.5 exposure and esophageal cancer. For each 10-μg/m3 increase in PM2.5, the HR was 1.16 (95% CI: 1.04–1.30) for esophageal cancer incidence. Compared with the first quarter of PM2.5 exposure, participants in the highest quarter had a 1.32-fold higher risk for esophageal cancer, with an HR of 1.32 (95% CI: 1.01–1.72). The population attributable risk because of annual average PM2.5 concentration ≥ 35 μg/m3 was 23.3% (95% CI: 6.6–40.0%), higher than the risks attributable to lifestyle risk factors.

Conclusions: This large prospective cohort study of Chinese adults found that long-term exposure to particulate matter (PM2.5) was associated with an elevated risk of esophageal cancer. With stringent air pollution mitigation measures in China, a large reduction in the esophageal cancer disease burden can be expected.

Prof. Dr. J. Lv or Prof. Dr. L. Li, Department of Epidemiology and Biostatistics, Peking University Health Science Center, Beijing, China, E-Mail: lvjun@bjmu.edu.cn or E-Mail: lmlee@vip163.com

or

Prof. Dr. H. Kan, Department of Environmental Health, School of Public Health, Fudan University, Shanghai, China, E-Mail: kanh@fudan.edu.cn

DOI: 10.1053/j.gastro.2023.03.233

Back to overview

this could be of interest:

Triple-hormone-receptor agonist retatrutide for obesity – A phase 2 trial

N Engl J Med. 2023;389(6):514–26

Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: Two multicenter, open-label, randomized controlled, non-inferiority trials

Lancet Gastroenterol Hepatol. 2023;8(7):623–34

More articles on the topic